Phase II Study of Tetrathiomolybdate (TM) in Patients With Breast Cancer
Status:
Active, not recruiting
Trial end date:
2022-06-01
Target enrollment:
Participant gender:
Summary
Patients with moderate to high risk primary breast cancer (Stage II with more than 4 lymph
nodes involved with cancer) III or Stage IV (without evidence of disease) will take
tetrathiomolybdate (TM) pills for two years.
The objectives of the study are to:
- Assess the safety and tolerability of tetrathiomolybdate in patients with breast cancer
at high risk of tumor recurrence.
- Observe the disease-free survival of patients in this trial.
- Conduct background scientific experiments on tumor tissue and blood of patients in this
study
Phase:
Phase 2
Details
Lead Sponsor:
Memorial Sloan Kettering Cancer Center Weill Medical College of Cornell University